Journal of Cardiothoracic and Vascular Anesthesia
Volume 26, Issue 1 , Pages 3-10, February 2012

The Year in Cardiothoracic and Vascular Anesthesia: Selected Highlights From 2011

  • Prakash A. Patel, MD

      Affiliations

    • Cardiovascular and Thoracic Section, Department of Anesthesiology and Critical Care, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
  • ,
  • Harish Ramakrishna, MD, FASE

      Affiliations

    • Cardiac Anesthesia, Mayo Clinic, Scottsdale, AZ
  • ,
  • Michael Andritsos, MD

      Affiliations

    • Department of Anesthesiology, The Ohio State University, Columbus, OH
  • ,
  • Tygh Wyckoff, MD

      Affiliations

    • Cardiovascular and Thoracic Section, Department of Anesthesiology and Critical Care, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
  • ,
  • Hynek Riha, MD, DEAA, FCCP

      Affiliations

    • Department of Anesthesiology and Intensive Care Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
  • ,
  • John G.T. Augoustides, MD, FASE, FAHA

      Affiliations

    • Cardiovascular and Thoracic Section, Department of Anesthesiology and Critical Care, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
    • Corresponding Author InformationAddress reprint requests to John G.T. Augoustides, MD, FASE, FAHA, Cardiothoracic Section, Anesthesiology and Critical Care, Dulles 680, HUP, 3400 Spruce Street, Philadelphia, PA 19104-4283

There have been rapid advances in oral anticoagulation. The oral factor Xa inhibitors rivaroxaban and apixaban and the oral direct thrombin inhibitor dabigatran recently have been rigorously evaluated. These novel anticoagulants will usher in a new paradigm for perioperative anticoagulation. Perioperative blood conservation in cardiac surgery recently has been highlighted in the updated guidelines by the Society of Cardiovascular Anesthesiologists and the Society of Thoracic Surgeons. These recommendations reflect a comprehensive evaluation of the recent evidence to optimize transfusion practice. Transcatheter mitral valve repair continues to mature. Transcatheter aortic valve implantation for aortic stenosis has entered the clinical mainstream, with randomized trials showing its superiority over medical management and its equivalency to surgical valve replacement in high-risk patients. This transformational technology represents a major leadership opportunity for the cardiac anesthesiologist. Minimally invasive valve surgery has shown effectiveness in high-risk patients. Radial access is equivalent to femoral access for percutaneous coronary intervention in acute coronary syndromes but significantly reduces the risk of local vascular complications. Recent trials have further clarified the roles of medical therapy, percutaneous coronary intervention, and coronary artery bypass surgery in patients with significant coronary artery disease and left ventricular dysfunction. The past year has witnessed major advances in cardiovascular practice with new drugs, new devices, and new guidelines. The coming year most likely will advance these achievements to enhance the care of patients.

Key Words:  factor Xa inhibitor , rivaroxaban , apixaban , direct thrombin inhibitor , dabigatran , blood conservation guidelines , aminocaproic acid , tranexamic acid , antifibrinolytics , erythropoietin , clopidogrel , platelet blockade , point-of-care testing , fresh frozen plasma , factor concentrates , leukoreduction , blood salvage , minimally invasive surgery , thoracic endovascular repair , cardiopulmonary bypass , coronary artery bypass surgery , ultrafiltration , microplegia , transcatheter mitral valve repair , transcatheter aortic valve implantation , percutaneous coronary intervention , radial artery , femoral artery , heart failure

 

PII: S1053-0770(11)00708-7

doi:10.1053/j.jvca.2011.10.005

Journal of Cardiothoracic and Vascular Anesthesia
Volume 26, Issue 1 , Pages 3-10, February 2012